Hyperhidrosis Treatment by Body Site

Treatment starts with the diagnosis and the body site#

“Hyperhidrosis treatment” is not one intervention. Before symptoms are treated as primary hyperhidrosis, secondary causes need to be considered. Current FDA labeling for Botox explicitly calls for evaluating potential causes, giving hyperthyroidism as an example, to avoid treating a symptom without diagnosing or treating the underlying disease.[6]

The body site changes the evidence. Qbrexza and Botox have U.S. indications for primary axillary hyperhidrosis. Tap-water iontophoresis has controlled evidence for palms and feet. Aluminum chloride studies span several sites and formulations. Oral anticholinergics can affect sweating beyond one treated area, but their systemic adverse effects also extend beyond one area.

This page is an evidence map, not a step-by-step prescription.

Aluminum chloride is a topical starting point with site-specific data#

Aluminum chloride antiperspirants reduce sweating at the treated skin surface. In a randomized half-side trial of 20 people with plantar hyperhidrosis, both 12.5% and 30% concentrations reduced sweat production over 6 weeks, and the researchers favored the lower concentration because both were effective.[1]

The finding supports topical treatment but does not prove that one percentage is best for underarms, palms, and feet. Irritation, formulation, body site, and maintenance all affect the tradeoff. See Drysol and aluminum chloride evidence for the study limits.

Qbrexza has 4-week controlled evidence for underarm sweating#

Qbrexza is a prescription glycopyrronium cloth labeled for primary axillary hyperhidrosis in adults and children age 9 and older. In two phase 3 randomized trials totaling 697 participants, patient-reported sweating severity improved more often with glycopyrronium cloth than with vehicle at week 4.[2]

The same studies and current label document anticholinergic effects including dry mouth, pupil dilation, urinary hesitation, blurred vision, and reduced ability to cool the body in hot conditions.[2][8] See Qbrexza trial results and safety.

Iontophoresis is a repeated-session option for palms and soles#

Tap-water iontophoresis uses controlled electrical current through water. A randomized sham-controlled trial of 29 people with palmar hyperhidrosis found substantially more clinical improvement with active iontophoresis after 10 sessions over 2 weeks.[3] A systematic review of palmar hyperhidrosis treatments also found symptom relief with regularly administered iontophoresis, while emphasizing that the evidence base remains limited.[4]

The treatment requires repeated sessions and device-specific safety screening. It should not be advertised as a one-session cure or reduced to a consumer-brand ranking. See iontophoresis machines: evidence and limits.

Botox has placebo-controlled evidence for severe primary axillary disease#

In a 320-person randomized trial, intradermal botulinum toxin A reduced axillary sweat production and produced more responders than placebo through 16 weeks.[5] Current U.S. labeling indicates Botox for adults with severe primary axillary hyperhidrosis that has not been managed adequately with topical agents.[6]

Botox is temporary, professionally administered, and accompanied by product-specific warnings, including a boxed warning about distant spread of toxin effect. See Botox for sweaty armpits.

Oral oxybutynin can improve sweating but adds systemic burden#

Oxybutynin is an oral anticholinergic used off-label in hyperhidrosis. A randomized placebo-controlled trial enrolled 62 people with localized or generalized hyperhidrosis. Sixty percent of the oxybutynin group and 27% of the placebo group improved by at least one HDSS point, and quality-of-life scores improved more with oxybutynin.[7]

The trial lasted 6 weeks, was small, and could have been partly unblinded because dry mouth is recognizable. Oxybutynin labeling also documents dry mouth, constipation, blurred vision, urinary-retention risk, and heat illness from reduced sweating in high temperatures.[9] A clinician must assess contraindications and drug interactions.

Procedures and surgery need their own evidence review#

Microwave thermolysis, local sweat-gland procedures, and sympathectomy are not interchangeable with topical or device treatments. They differ in reversibility, anesthesia, evidence quality, adverse effects, and risk of compensatory sweating. Each needs a procedure-specific discussion rather than a universal ranking; see the miraDry evidence and recovery review for one underarm-specific example.

Bottom line#

The most defensible treatment map is body-site-specific. Topical aluminum chloride has small-trial support across focal sites; Qbrexza has short controlled trials for underarms; iontophoresis has controlled evidence for hands and feet; Botox has placebo-controlled evidence for severe underarm disease; and oral oxybutynin has a small randomized trial with systemic tradeoffs.[1][2][3][5][7]

This article is educational. It cannot determine whether sweating is primary or secondary, select a treatment, or assess contraindications for an individual reader.

References#

1. Streker M, Reuther T, Hagen L, Kerscher M. Hyperhidrosis plantaris: a randomized, half-side trial of aluminum chloride concentrations. PubMed PMID 21848980

2. Pariser DM, Hebert AA, Drew J, et al. Patient-reported outcomes from the ATMOS-1 and ATMOS-2 glycopyrronium trials. PMC full text

3. Kim DH, Kim TH, Lee SH, Lee AY. Tap-water iontophoresis for palmar hyperhidrosis: randomized sham-controlled trial. PubMed PMID 29200761

4. McConaghy JR, Fosselman D. The treatment of palmar hyperhidrosis: a systematic review. PubMed PMID 34653261

5. Naumann M, Lowe NJ. Multicenter randomized trial of botulinum toxin A for bilateral primary axillary hyperhidrosis. PubMed PMID 11557704

6. U.S. National Library of Medicine. Botox prescribing information, revised February 2026. DailyMed label

7. Schollhammer M, Brenaut E, Ménard-Andivot N, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized placebo-controlled trial. PubMed PMID 26114588

8. U.S. National Library of Medicine. Qbrexza (glycopyrronium cloth) prescribing information, revised November 2022. DailyMed label

9. U.S. National Library of Medicine. Oxybutynin chloride prescribing information. DailyMed label